Role of LRRK2 kinase dysfunction in Parkinson disease

被引:28
|
作者
Kumar, Azad [1 ]
Cookson, Mark R. [1 ]
机构
[1] NIA, Cell Biol & Gene Express Unit, Neurogenet Lab, NIH, Bethesda, MD 20892 USA
来源
关键词
AUTOSOMAL-DOMINANT PARKINSONISM; NORTH-AFRICAN FAMILIES; G2019S MUTATION; DOPAMINERGIC-NEURONS; ALPHA-SYNUCLEIN; LEUCINE-RICH-REPEAT-KINASE-2; LRRK2; CYTOPLASMIC LOCALIZATION; CAENORHABDITIS-ELEGANS; R1441C MUTATION; COMMON FOUNDER;
D O I
10.1017/S146239941100192X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Parkinson disease is a common and usually sporadic neurodegenerative disorder. However, a subset of cases are inherited and, of these, mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) are the most frequent genetic cause of disease. Here, we will discuss recent progress in understanding how LRRK2 mutations lead to disease and how this might have therapeutic implications. The effect of mutations on LRRK2 enzyme function provides clues as to which functions of the protein are important to disease. Recent work has focused on the kinase and GTP-binding domains of LRRK2, and it is assumed that these will be therapeutically important, although there is a substantial amount of work to be done to address this hypothesis.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Role of LRRK2 and SNCA in autosomal dominant Parkinson's disease in Turkey
    Kessler, Christoph
    Atasu, Burcu
    Hanagasi, Hasmet
    Simon-Sanchez, Javier
    Hauser, Ann-Kathrin
    Pak, Meltem
    Bilgic, Basar
    Erginel-Unaltuna, Nihan
    Gurvit, Hakan
    Gasser, Thomas
    Lohmann, Ebba
    PARKINSONISM & RELATED DISORDERS, 2018, 48 : 34 - 39
  • [42] LRRK2: Understanding the role of common and rare variants in Parkinson's disease
    Sharma, Manu
    Kruger, Rejko
    Gasser, Thomas
    MOVEMENT DISORDERS, 2012, 27 (04) : 475 - 475
  • [43] Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease
    Nichols, R. Jeremy
    Dzamko, Nicolas
    Hutti, Jessica E.
    Cantley, Lewis C.
    Deak, Maria
    Moran, Jennifer
    Bamborough, Paul
    Reith, Alastair D.
    Alessi, Dario R.
    BIOCHEMICAL JOURNAL, 2009, 424 : 47 - 60
  • [44] The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases
    Tsafaras, George
    Baekelandt, Veerle
    NEUROBIOLOGY OF DISEASE, 2022, 172
  • [45] Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease Models
    Kramer, Thomas
    Lo Monte, Fabio
    Goering, Stefan
    Amombo, Ghislaine Marlyse Okala
    Schmidt, Boris
    ACS CHEMICAL NEUROSCIENCE, 2012, 3 (03): : 151 - 160
  • [46] Genetics of Parkinson's disease: LRRK2 on the rise
    Brice, A
    BRAIN, 2005, 128 : 2760 - 2762
  • [47] Hypercholinergic activity in LRRK2 Parkinson's disease
    Bohnen, Nicolaas I.
    Albin, Roger L.
    LANCET NEUROLOGY, 2018, 17 (04): : 290 - 291
  • [48] Metabolomic analysis in LRRK2 Parkinson's disease
    Johansen, K. K.
    Matson, W.
    Beal, F.
    Aasly, J. O.
    Bogdanov, M.
    MOVEMENT DISORDERS, 2007, 22 : S187 - S187
  • [49] Inhibitors of LRRK2 Kinase Activity To Probe the Treatment Option in Parkinson's Disease
    Rautio, Jarkko
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (22) : 9414 - 9415
  • [50] Inhibitors of LRRK2 as Treatment for Parkinson's Disease
    Abdel-Magid, Ahmed F.
    ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (09): : 701 - 702